Study of RGL-270 with or without Adebelimab for high-risk solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new treatment (RGL-270) alone or with another drug (Adebelimab) to prevent cancer from coming back after surgery. It is for people with solid tumors that have a high chance of returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove a solid tumor and are at high risk of it coming back
- You are between 18 and 75 years old
- You have finished standard treatments after surgery, or you cannot have them
- You are able to provide tumor and blood samples for testing
- You agree to use contraception for 6 months after your last treatment
- Your cancer has no signs of return on scans within 14 days before first vaccine dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cancer vaccine (RGL-270) combined with immunotherapy drugs for advanced non-small cell lung cancer. The vaccine is designed to train your immune system to recognize and fight your specific cancer.
This trial tests a new drug (GRWD5769) that may help your immune system fight cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including certain types of cervical, liver, and other cancers.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests an experimental injection called GKL-006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and helps shrink or control the cancer.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Hear when a new Tumor, Solid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.